Why the study?
Questions remain regarding whether polio vaccines are equally protective against immunologically different strains of the same serotype.
Does a booster dose of IPV improve neutralizing antibody titers against heterologous strains of type 1 poliovirus in vaccine-immunized individuals?
Population
Sera from vaccine-immunized individuals and animals
Comparison
Neutralization against homologous vs heterologous strains of serotype 1 polioviruses, before and after IPV booster
Design
Neutralization assay study
Authors
Loading...
Animal data are hypothesis-generating for IPV boosters against heterologous strains; prospective human trials needed before practice change.
Does a booster dose of IPV improve neutralizing antibody titers against heterologous strains of type 1 poliovirus in vaccine-immunized individuals?
Potency of polio vaccines made from serologically different strains should be determined against both homologous and heterologous challenge viruses due to antigenic diversity.
Kouiavskaia et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: